Recently, the pivotal ECHELON-2 trial, a randomized phase III study evaluating the use of BV in the frontline treatment of CD30-positive PTCL, showed a statistically significant improvement in both progression-free survival and OS versus standard CHOP therapy [9]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.